OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program

類似資料

• OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT
  著者:: Aurora, SK, 等
  出版事項: (2013)
• The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program
  著者:: Silberstein, S, 等
  出版事項: (2013)
• OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients without medication overuse
  著者:: Diener, HC, 等
  出版事項: (2013)
• Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
  著者:: Silberstein, Stephen D, 等
  出版事項: (2015)
• OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
  著者:: Dodick, D, 等
  出版事項: (2013)